ReviewFrontiers in chemistry2026
Antibody-drug conjugates for infectious and neglected tropical diseases: chemical design principles, target biology, and translational challenges.
Review in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) are established precision treatments in oncology. Nevertheless, their application to infectious diseases and neglected tropical diseases (NTDs) is still an emerging field. In contrast to cancer cells, pathogens exhibit dynamic surface features and distinct intracellular environments, necessitating a complete redesign of the ADC architecture. This review combines chemical concepts and biological insights to outline a "pathogen-centric" framework for bacterial, viral, and parasite illnesses. We analyze target selection across various diseases, emphasizing structural accessibility and antigen stability as critical factors. A comprehensive evaluation of ADC chemical architecture is provided, focusing on linkers that respond to pathogen-specific enzymatic or environmental triggers, alongside a range of non-cytotoxic payloads, notably redox-active metallo-drugs designed to overcome antimicrobial resistance. We rigorously analyze the shift from empirical screening to AI-enhanced and structurally-informed design processes. Lastly, we look at the particular translation concerns in this field, such as the Payload Paradox and the complications that come with internalization. We discuss also sustainable biomanufacturing methods that will ensure equitable and fair access to the products. This study offers a chemistry-based framework that outlines the essential ideas required for the advancement of antibody-drug conjugates (ADCs) as targeted anti-infectives for major global infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.